The global T-cell specific surface glycoprotein CD28 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). CD28 is a glycoprotein of 90 kDa and occurs naturally as a disulfide-linked homodimer of a polypeptide that contains a single Ig-like extracellular domain. Additionally, it is a member of the Ig superfamily and is expressed on T cells that provide co-stimulatory signals which are required for T cell activation and survival. Furthermore, it acts as a major costimulation pathway for naive T-cell activation while playing a central role in immune responses against pathogens, autoimmune diseases, and graft rejection.

Moreover, it enhances the production of IL4 and IL10 in T-cells in conjunction. Additionally, it signals the initial activation of naive CD4 T cells by increasing the sensitivity of the T cell to antigen receptor engagement. Furthermore, CD28 is expressed on 50% of CD8+ T cells and more than 80% CD4+ T cells in humans and supports to kill cancer cells that are virally infected or that are under damage. Hence, the factor driving the growth of the market is the prevalence of cancer.

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Some major players in the market include Bristol-Myers Squibb Co., and Johnson and Johnson Services, Inc., among others. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Amgen Inc., and Johnson & Johnson Services, Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global T-Cell Specific Surface Glycoprotein CD28 Market Report by Segment

By Type

• FPT-155

• FR-104

• Lulizumab Pegol

• Others

By Application 

• Plaque Psoriasis

• Solid Tumor

• Acute Renal Failure(ARF)

• Others

Global T-Cell Specific Surface Glycoprotein CD28 Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa